Cargando…

Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects

Mucin 1 (MUC1) has received increasing attention due to its high expression in breast cancer, in which MUC1 acts as a cancer antigen. Our group has been committed to the development of small-molecule TLR7 (Toll-like receptor 7) agonists, which have been widely investigated in the field of tumor immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shuquan, Liu, Yu, Zhou, Ji, Wang, Jiaxin, Jin, Guangyi, Wang, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741412/ https://www.ncbi.nlm.nih.gov/pubmed/36499455 http://dx.doi.org/10.3390/ijms232315130

Ejemplares similares

Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects
por: Liu, Yu, et al.
Publicado: (2020)

Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity
por: Seya, Tsukasa, et al.
Publicado: (2015)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity
por: Ren, Sumei, et al.
Publicado: (2022)

Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine
por: Gableh, Fateme, et al.
Publicado: (2016)

Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants
por: Kumar, Sudeep, et al.
Publicado: (2019)

Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
por: Bhagchandani, Sachin, et al.
Publicado: (2021)

Enhancement of SARS-CoV-2 vaccine-induced immunity by a Toll-like receptor 7 agonist adjuvant
por: Li, Gen, et al.
Publicado: (2023)

Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
por: Wang, Xiaodong, et al.
Publicado: (2018)

Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases
por: Yang, Jing-Xing, et al.
Publicado: (2022)

Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib
por: Gao, Ningning, et al.
Publicado: (2016)

Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy
por: Tang, Li, et al.
Publicado: (2019)

Transcriptomal signatures of vaccine adjuvants and accessory immunostimulation of sentinel cells by toll-like receptor 2/6 agonists
por: Salyer, Alex C. D., et al.
Publicado: (2018)

Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
por: Chakraborty, Samik, et al.
Publicado: (2023)

Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates
por: Chan, Michael, et al.
Publicado: (2009)

The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm
por: Ghimire, Tirth Raj
Publicado: (2015)

Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists
por: Manrique, Soraya Zorro, et al.
Publicado: (2016)

Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
por: Hotz, Christian, et al.
Publicado: (2012)

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants
por: Shanmugam, Arulkumaran, et al.
Publicado: (2012)

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients
por: Melssen, Marit M., et al.
Publicado: (2019)

Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma
por: Zhu, Jiang, et al.
Publicado: (2015)

A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma
por: Lin, Guimiao, et al.
Publicado: (2015)

The Toll‐like receptor 7 agonist imiquimod increases ethanol self‐administration and induces expression of Toll‐like receptor related genes
por: Lovelock, Dennis F., et al.
Publicado: (2022)

Toll like-receptor agonist Pam(3)Cys modulates the immunogenicity of liposomes containing the tuberculosis vaccine candidate H56
por: Kennerknecht, Kathrin, et al.
Publicado: (2020)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Natural toll-like receptor agonists in prophylactic vaccines for dendritic cell activation
por: Peng, Paul, et al.
Publicado: (2015)

Biopersistence and Brain Translocation of Aluminum Adjuvants of Vaccines
por: Gherardi, Romain Kroum, et al.
Publicado: (2015)

Toll-Like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular Docking Studies
por: Yu, Hui, et al.
Publicado: (2013)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Combining vasculature disrupting agent and toll-like receptor 7/8 agonist for cancer therapy
por: Seth, Anushree, et al.
Publicado: (2016)

Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
por: Angelopoulou, Athina, et al.
Publicado: (2020)

Synthetic Toll-like Receptors 7 and 8 Agonists: Structure–Activity Relationship in the Oxoadenine Series
por: Evans, Jay T., et al.
Publicado: (2019)

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
por: Patinote, Cindy, et al.
Publicado: (2020)

Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer
por: Ye, Jian, et al.
Publicado: (2022)

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
por: Patel, Sapna P, et al.
Publicado: (2021)

BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
por: Kaushik, Deepender, et al.
Publicado: (2020)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Physicochemical properties and adsorption state of aluminum adjuvants with different processes in vaccines
por: Bo, Cunpei, et al.
Publicado: (2023)

Surface Immunogenic Protein of Streptococcus Group B is an Agonist of Toll-Like Receptors 2 and 4 and a Potential Immune Adjuvant
por: Diaz-Dinamarca, Diego A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bpulc3a1mk545k28vtro2hdfp1